Overview

RAndomized Therapy In Status Epilepticus

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effectiveness and safety of an investigational product, IV ganaxolone, to treat subjects with status epilepticus.
Phase:
Phase 3
Details
Lead Sponsor:
Marinus Pharmaceuticals
Treatments:
Ganaxolone